TransMedics Group (NASDAQ:TMDX) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

TransMedics Group (NASDAQ:TMDX) announced its earnings results on Tuesday. The company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06), FiscalAI reports. TransMedics Group had a net margin of 22.69% and a return on equity of 16.58%. The business had revenue of $189.95 million during the quarter, compared to analyst estimates of $184.00 million. During the same period in the previous year, the firm earned $0.92 earnings per share. The business’s revenue was up 20.7% compared to the same quarter last year.

Here are the key takeaways from TransMedics Group’s conference call:

• Record second-quarter performance: Revenue reached approximately $190 million, up 21% year over year, while service revenue rose 29% and logistics revenue increased 39%. The company attributed the strength to higher OCS utilization, new centers, logistics market-share gains, pricing adjustments, and improved fleet efficiency.
• TransMedics raised the low end of its 2026 revenue guidance to $737 million-$757 million, representing 22%-25% growth, and ended the quarter with approximately $473 million in cash and equivalents. The guidance excludes meaningful contributions from PAD Aviation, ENHANCE Part B, and DENOVO.
• Management is prioritizing long-term growth investments over near-term profitability, including OCS Kidney, next-generation OCS, clinical programs, international infrastructure, and new facilities. As a result, full-year adjusted operating-margin guidance was reduced to approximately 12.5%-14% from the prior expectation of about 16%.
• The OCS Kidney program is entering engineering and manufacturing verification, with pre-IDE discussions underway and first clinical experience targeted for 2027. ENHANCE Heart Part B and DENOVO Lung remain dependent on FDA review; management said only a handful of cases have been completed so far and expects meaningful contribution later than originally anticipated.
• TransMedics closed its investment in Germany-based PAD Aviation to establish a European transplant-logistics network, with Italy the initial commercial focus and reimbursement expected later in 2026 or early 2027. PAD is expected to be margin-dilutive initially, but provides European aviation licensing, pilots, fleet access, and eligibility for regional logistics tenders.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $77.00 on Thursday. The company has a market cap of $2.66 billion, a P/E ratio of 19.78 and a beta of 1.90. The business has a fifty day simple moving average of $73.14 and a 200-day simple moving average of $99.24. TransMedics Group has a 52 week low of $60.10 and a 52 week high of $156.00. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70.

Insiders Place Their Bets

In related news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the sale, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of large investors have recently bought and sold shares of TMDX. Kemnay Advisory Services Inc. bought a new stake in shares of TransMedics Group during the 4th quarter worth about $100,000. Empowered Funds LLC bought a new position in TransMedics Group in the 4th quarter valued at about $128,000. State of Wyoming raised its holdings in TransMedics Group by 20.6% in the 4th quarter. State of Wyoming now owns 824 shares of the company’s stock valued at $100,000 after acquiring an additional 141 shares during the period. Quarry LP lifted its position in TransMedics Group by 41.9% during the third quarter. Quarry LP now owns 959 shares of the company’s stock worth $108,000 after acquiring an additional 283 shares during the last quarter. Finally, Johnson Financial Group Inc. acquired a new stake in TransMedics Group during the third quarter worth approximately $65,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Weiss Ratings downgraded TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, July 28th. UBS Group cut their price target on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a report on Wednesday. Piper Sandler reiterated an “overweight” rating and set a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research report on Wednesday. TD Cowen reissued a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a report on Wednesday, July 1st. Finally, Oppenheimer lowered TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $124.18.

TransMedics Group News Roundup

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: TransMedics issued fiscal 2026 revenue guidance of $737 million to $757 million, above the approximately $733.6 million consensus estimate. Management also outlined an ambition to support 30,000 transplants annually by 2032, reinforcing the company’s long-term growth strategy. TransMedics 2026 revenue outlook
• Positive Sentiment: Second-quarter revenue increased 20.7% year over year to about $189.9 million, exceeding analyst expectations and indicating continued demand for the company’s organ-transplant technology. Piper Sandler reaffirmed its bullish rating, retaining an Overweight/Buy view and a $100 price target. TransMedics second-quarter results
• Neutral Sentiment: Analyst sentiment remains mixed. UBS lowered its price target from $80 to $77 and moved to a Neutral rating, while Piper cut its target from $120 to $100 despite maintaining its Overweight rating. Needham also issued a pessimistic forecast. Piper Sandler rating
• Negative Sentiment: Adjusted quarterly earnings of approximately $0.44 per share missed the $0.50 consensus estimate and declined from $0.92 a year earlier. Operating profit and net income also fell, while margins contracted and operating costs rose sharply, overshadowing the revenue beat and raised outlook. TransMedics earnings and margins
• Negative Sentiment: Rosen Law Firm announced an investigation into potential fiduciary-duty breaches by TransMedics’ directors and officers, adding legal and reputational risk for shareholders. Reported insider activity also showed multiple sales and no purchases over the past six months, which may weigh on sentiment. Rosen Law Firm investigation

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.